Journal of Clinical Oncology
Articles in this Issue
Does race predict adherence to relugolix among patients with prostate cancer? A Veterans Health Administration data analysis.
e17102 Background : Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral androgen deprivation therapy (ADT...
Distinct cellular interactions in the TNBC tumor microenvironment in association with PD-L1 expression and pathologic complete response based on spatial analysis.
e12544 Background: Immune-activated tumor microenvironments (TMEs), characterized by PD-L1 positivity or an abundance of tumor-infiltrating lymphocytes, a...
10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.
4019 Background: Inhibitors of Programmed Cell Death Protein-1 (PD-1) have demonstrated remarkable activity in dMMR/MSI-H...
The prevalence and outcomes of syndrome of inappropriate antidiuretic hormone secretion (SIADH) among patients hospitalized with lung cancer: Insights from the Nationwide Inpatient Sample.
e20103 Background: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication in cancer patients, contributing to substanti...
Evaluation of the effects of THC on migration, proliferation, and tumor growth in HPV-negative HNSCC.
e18062 Background: Head and neck squamous cell carcinoma (HNSCC) is a significant global health concern, with over 60,000 new cases and approximately 14,0...
Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer.
8018 Background: Since the Food and Drug Administration (FDA) approvals in 2021 and 2023, atezolizumab and pembrolizumab, respectively, became standard ma...
Mevrometostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
e17029 Background: Mevrometostat (M) is a potent and selective inhibitor of EZH2. Dose exploration of M + enzalutamide (E) + androgen deprivation therapy...
A first-in-human multi-center phase 1/2 study of a selective FGFR2/3 inhibitor, CGT4859, in patients with intrahepatic cholangiocarcinomas or other advanced solid tumors.
TPS3171 Background: Genetic alterations in fibroblast growth factor receptors 2 and 3 ( FGFR2/3 ) occur in nearly all cancer types...
Signatera ctDNA in stage II CRC: A retrospective comparison with traditional risk factors for survival and prognostic stratification.
e15641 Background: Stage II colorectal cancer (CRC) presents a clinical challenge due to variable recurrence risk and uncertain benefits of adjuvant chemo...
First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
2501 Background: CLDN6 is an oncofetal cell surface protein silenced in normal adult tissues but aberrantly activated in testicular, ovarian, non-small ce...
Exploring radiation pneumonitis mortality risk among patients with underlying lung disease.
e23138 Background: Radiation pneumonitis (RP) is an acute inflammatory reaction of the lung parenchyma following radiation therapy. Patients with intersti...
Impact of the eSyM symptom monitoring program on nurse telephone encounters across six cancer centers.
1541 Background: After developing an ePRO-based, EHR-integrated symptom monitoring program (eSyM) and implementing it across 6 health systems, we found lo...
Falcon: Exact Sciences’ multicancer early detection (MCED) real world evidence (RWE) registry.
TPS11189 Background: Earlier detection may reduce cancer morbidity and mortality by reducing the number of cancers diagnosed at advanced stages. Exact Sci...
Propensity score (PS) comparison between lisocabtagene maraleucel (liso-cel) plus ibrutinib combination therapy (combo) and liso-cel monotherapy (mono) cohorts from TRANSCEND CLL.
7037 Background: TRANSCEND CLL 004 (NCT03331198) is a phase 1/2, open-label, nonrandomized, multicohort study in adult patients (pt) with R/R chronic lymp...
Racial and ethnic disparities in the occurrence of second primary malignancies (SPMs) in early onset colorectal cancer (EOCRC).
e15685 Background: Early-onset colorectal cancer (EOCRC) (diagnosed before age 50) has been increasing in the United States, prompting a recent change in...
Efficacy of anti-PD-1 rechallenge in metastatic melanoma: A retrospective analysis.
e21544 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic melanoma, but a subset of patients experiences dise...
Meta-analysis of the cardiovascular adverse effects of bispecific antibodies in malignant hematology therapies.
e14503 Background: Bispecific antibodies (BsAbs), recombinant molecules that target two distinct antigens or epitopes, are...
Phase 1 results of Oncobax-AK in combination with ipilimumab/nivolumab in advanced clear cell renal cell carcinoma (ccRCC; NCT05865730).
4529 Background: Patients with advanced solid tumors who respond to immunotherapy are more likely to have Akkermansia spp (Akk) in...
Impact of immunotherapy on small cell lung cancer survival: A focus on treatment setting, race, and socioeconomics.
8102 Background: Immunotherapy has transformed the treatment landscape for many cancers, but its benefit in small cell lung cancer (SCLC) has remained mod...
Spatial transcriptomic profiling of the tumor microenvironment in EGFR and KRAS mutant non-small cell lung cancer.
8539 Background: Immune checkpoint inhibitors have greatly improved outcomes in advanced non-small cell lung cancer (NSCLC). However, patients with EGFR m...
Disparities in chemotherapy utilization among urban upper GI malignancy cancer patients at a safety-net hospital.
e23170 Background: Urban underserved populations face barriers to cancer treatment. Safety-net hospitals, serving vulnerable groups, often reveal disparit...
National trends in incidence of gastric cancer among older adults (70+) from 1990 to 2021 across 204 nations: A global burden of disease study.
e16080 Background: Gastric cancer presents global health challenges, with notable disparities in incidence and prevalence rates. This study examines trend...
A phase II efficacy and safety study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer.
5602 Background: HB0025, developed by Huaota, is a novel anti-PD-L1/VEGF bispecific antibody, with VEGFR1D2 linked at the N-terminal of anti- PD-L1 antibo...
Recent trends in cancer distribution and survival outcomes among adolescent and young adult patients: A national data analysis.
10561 Background: Cancer distribution varies significantly among adolescents and young adults (AYAs) aged 15 to 39. Understanding these trends is essentia...
Patterns of confirmatory germline testing in patients with somatic BRCA1/2 pathogenic variants across solid tumor types in a community oncology setting.
e23331 Background: Tumor mutation profiling serves as an essential diagnostic tool in oncology, facilitating the identification of targetable variants and...